LENZ · NASDAQ
LENZ Therapeutics (LENZ) Stock Price & Fundamentals
LENZ Therapeutics (LENZ) closed at $794.63 on Oct 9, 2026, down 0.78% from the previous close of $800.91.
Share price, past year
1Y +11.41%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $794.63 |
| Sep 30, 2026 | $782.61 |
| Aug 31, 2026 | $867.54 |
| Jul 31, 2026 | $851.52 |
| Jun 30, 2026 | $822.51 |
| May 29, 2026 | $777.00 |
| Apr 30, 2026 | $735.71 |
| Mar 31, 2026 | $734.38 |
| Feb 27, 2026 | $753.90 |
| Jan 30, 2026 | $809.07 |
| Dec 31, 2025 | $781.37 |
| Nov 28, 2025 | $747.30 |
| Oct 31, 2025 | $718.49 |
Key statistics
- Market cap
- $24.96B
- P/E (TTM)
- —
- EPS (TTM)
- −$4.13
- Revenue (TTM)
- $21.48M
- Net income (TTM)
- −$126.00M
- Shares outstanding
- 31.4M
- Dividend yield
- —
- 52-week range
- $708.58 – $867.54
LENZ Therapeutics's market cap is $24.96B, based on a share price of $794.63 and 31.4M shares outstanding as of Jun 30, 2026.
Financials
LENZ Therapeutics reported revenue of $19.09M for fiscal 2025.
LENZ Therapeutics reported a net loss of $82.13M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $19.09M | — | −$82.13M | −430.3% | −$2.85 | −$70.00M |
| FY2024ended Dec 31, 2024 | $0.00 | — | −$49.77M | — | −$2.34 | −$59.86M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $5.49M | −$31.92M | −$1.02 |
| Q1 FY2026ended Mar 31, 2026 | $1.90M | −$41.49M | −$1.32 |
| Q4 FY2025ended Dec 31, 2025 | $1.59M | −$35.90M | −$1.20 |
| Q3 FY2025ended Sep 30, 2025 | $12.50M | −$16.70M | −$0.59 |
| Q2 FY2025ended Jun 30, 2025 | $5.00M | −$14.91M | −$0.53 |
| Q1 FY2025ended Mar 31, 2025 | $0.00 | −$14.62M | −$0.53 |
| Q3 FY2024ended Sep 30, 2024 | $0.00 | −$10.22M | −$0.38 |
| Q2 FY2024ended Jun 30, 2024 | $0.00 | — | — |
Company profile
- Name
- LENZ Therapeutics, Inc.
- Ticker
- LENZ
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 201 Lomas Santa Fe Drive, Suite 300, Solana Beach, CA 92075
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001815776
Recent SEC filings
- Aug 11, 2026
- Aug 11, 2026
- Jul 2, 2026
- Jun 12, 2026
- May 11, 2026
- May 11, 2026
- Mar 24, 2026
- Mar 24, 2026
Frequently asked questions
What is LENZ Therapeutics's stock price?
LENZ Therapeutics (LENZ) closed at $794.63 on Oct 9, 2026, down 0.78% from the previous close of $800.91.
What is LENZ Therapeutics's market cap?
LENZ Therapeutics's market cap is $24.96B, based on a share price of $794.63 and 31.4M shares outstanding as of Jun 30, 2026.
How much revenue does LENZ Therapeutics make?
LENZ Therapeutics reported revenue of $19.09M for fiscal 2025.
Does LENZ Therapeutics pay a dividend?
LENZ Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from LENZ Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures